The Latest Breaking News from Incyte

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

The U.S.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent.  The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2…

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter: